Table 1 Demographic and clinical characteristics in patients at baseline in overall cohort and in groups A and B
Overall (n 564) | Group A (n 169) | Group B (n 395) | p* | |
|---|---|---|---|---|
Gender (% m/% f) | 44.9/55.1 | 43.5/56.5 | 45.1/54.9 | 0.22 |
Age (years) | 64.7 ± 8.8 | 64.4 ± 8.4 | 65.2 ± 9.2 | 0.21 |
Duration of diabetes (years) | 9.0 ± 4.1 | 9.2 ± 4.5 | 8.9 ± 4.0 | 0.19 |
Smoker (%) | 25.7 | 26.4 | 25.2 | 0.18 |
BMI (kg/m2) | 29.3 ± 4.6 | 29.6 ± 4.4 | 29.2. ± 4.7 | 0.32 |
HbA1c (%) | 7.4 ± 1.3 | 7.4 ± 1.4 | 7.5 ± 1.0 | 0.26 |
SBP (mmHg) | 135.9 ± 13.2 | 134.6 ± 15.6 | 136. ± 16.1 | 0.21 |
DBP (mmHg) | 78.2 ± 7.3 | 77.5 ± 6.2 | 79.9 ± 7.0 | 0.27 |
Tot. cholesterol (mg/dl) | 196 ± 41.2 | 198.4 ± 43.6 | 195.4 ± 40.5 | 0.19 |
HDL-C (mg/dl) | 48.8 ± 11.9 | 48.9 ± 12,4 | 48.4 ± 11.7 | 0.25 |
LDL-C (mg/dl) | 118.7 ± 31.3 | 119.5 ± 32.5 | 117.6 ± 30.9 | 0.16 |
Triglycerides (mg/dl) | 149.3 ± 80.8 | 146.9 ± 83.4 | 150.1 ± 81.7 | 0.17 |
UAlb (mg/24 h) | 143.1 ± 136.3 | 139.5 ± 140.4 | 144.4 ± 131.5 | 0.12 |
GFR (mL/min/1.73 m2) | 66.4 ± 24.3 | 66.1 ± 28.1 | 67.2 ± 25.2 | 0.22 |
Anti-hypertensive drugs (%) | 84.5 % | 83.5 | 85.3 | 0.19 |
OHA (%) | 67.7 | 66.5 | 68.3 | 0.20 |
Insulin (%) | 29.4 | 30.1 | 28.8 | 0.18 |
Statins (%) | 29.9 | 100 | 0 | |
Aspirin and/or other antiplatelet drug (%) | 42.8 | 43.1 | 42.5 | 0.24 |